Evaluation of MRI enhancement in different tissues of prostate using pharmacokinetic model
10.3969/j.issn.1005-1678.2017.08.147
- VernacularTitle:应用药物代谢动力学模型评价前列腺不同组织的MRI增强作用
- Author:
Yangrui XIAO
;
Bingrong LI
;
Jianping LIU
- Keywords:
pharmacokinetics model;
different tissues of prostate;
MRI enhancement;
clinical diagnosis
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(8):344-345
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of MRI on the enhancement of normal prostate, benign prostatic hyperplasia and prostate cancer by pharmacokinetic model. Methods A total of 80 patients with prostate cancer diagnosed by pathological examination in Lishui Central Hospital from February 2015 to August 2016 were selected as the subjects in this study. 1.5T superconducting magnetic resonance imaging was used, the serial needle was FMPSPGR for enhanced scan of the prostate of the patient, interlayer was 2 mm and the thickness was 7 mm, continuous scanning was performed 35 times, after the elbow vein indwelling catheter, the Gd-DTPA was injected rapidly at the beginning of the scan according to the 0.1 mmol/kg dose. By scanning data, inspection data transfer and workstation for patients with scanning results were analyzed using two room pharmacokinetic model calculation of ROI, the patients of normal prostate peripheral zone, benign prostatic hyperplasia and prostate cancer index, maximum enhancement of contrast agent distribution index, exchange rate, contrast absorption amplitude. Results After a series of calculation and analysis, the maximum enhancement index of prostate cancer, the distribution index of contrast agent, the contrast agent exchange rate and the contrast agent absorption index of prostate cancer were the highest. The maximum enhancement index, contrast agent distribution index, contrast agent exchange rate and contrast agent absorption index were significantly lower than those of prostate cancer, The difference was statistically significant (P<0.05). The indexes of normal prostate were significantly lower than those of benign prostatic hyperplasia (BPH) and prostate cancer (P<0.05). Conclusion The application of drug evaluation pharmacokinetic model of prostate MRI in different tissues to enhancing effect on patients with prostate tumor and non tumor tissue blood supply characteristics more accurately describe and differentiate, to improve the accuracy of identification and diagnosis of prostate in clinical treatment in a certain extent, with further clinical promotion and application significance.
